Alzheimer's disease: Evidence for the expression of interleukin-33 and its receptor ST2 in the brain

Journal of Alzheimer's Disease

Volumn 40, Issue 2, 2014, Pages 297-308

  Xiong, Zhi ^a   Thangavel, Ramasamy ^a,b   Kempuraj, Duraisamy ^a,b   Yang, Evert ^b   Zaheer, Smita ^b   Zaheer, Asgar ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Alzheimer's disease; amyloid plaques; glia maturation factor; IL 33; neurofibrillary tangles; ST2

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; INTERLEUKIN 33; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); CELL SURFACE RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; NEUROFILAMENT PROTEIN; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ARTICLE; ASTROCYTE; CELL CULTURE; CONTROLLED STUDY; ENTORHINAL CORTEX; FLOW CYTOMETRY; GLIA CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INCUBATION TIME; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGED; ANIMAL; BRAIN; C57BL MOUSE; CYTOLOGY; DRUG EFFECTS; FEMALE; MALE; METABOLISM; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ASTROCYTES; BRAIN; FEMALE; FLOW CYTOMETRY; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; INTERLEUKINS; MALE; MICE; MICE, INBRED C57BL; NEUROFILAMENT PROTEINS; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; RECEPTORS, CELL SURFACE;

EID: 84901933225     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132081     Document Type: Article

References (38)

1. Farfara D, Lifshitz V, Frenkel D (2008) Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med 12, 762-780. (Pubitemid 351718063)
2. Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, March A, Ait-Ghezala G, Mullan MJ (2010) Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 7, 17.
3. Carter MD, Simms GA,Weaver DF (2010) The development of new therapeutics for Alzheimer's disease. Clin Pharmacol Ther 88, 475-486.
4. Korczyn AD (2012) Why have we failed to cure Alzheimer's disease? J Alzheimers Dis 29, 275-282.
5. Thangavel R, Stolmeier D, Yang X, Anantharam P, Zaheer A (2011) Expression of glia maturation factor in neuropathological lesions of Alzheimer's disease. Neuropathol Appl Neurobiol 38, 572-581.
6. Medeiros R, LaFerlaFM(2013) Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol 239, 133-138.
7. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT (2010) Inflammation and Alzheimer's disease. Arch Pharm Res 33, 1539- 1556.
8. Hudson CA, Christophi GP, Gruber RC, Wilmore JR, Lawrence DA, Massa PT (2008) Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol 84, 631-643.
9. Van Eldik LJ, Thompson WL, Ralay Ranaivo H, Behanna HA, Martin Watterson D (2007) Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int Rev Neurobiol 82, 277-296.
10. Stolmeier D, Thangavel R, Anantharam P, Khan MM, Kempuraj D, Zaheer A (2013) Glia maturation factor expression in hippocampus of human Alzheimer's disease. Neurochem Res 38, 1580-1589.
11. Zaheer S, Thangavel R, Sahu SK, Zaheer A (2011) Augmented expression of glia maturation factor in Alzheimer's disease. Neuroscience 194, 227-233.
12. Yasuoka S, Kawanokuchi J, Parajuli B, Jin S, Doi Y, Noda M, Sonobe Y, Takeuchi H, Mizuno T, Suzumura A (2011) Production and functions of IL-33 in the central nervous system. Brain Res 1385, 8-17.
13. Moulin D, Donze O, Talabot-Ayer D, Mezin F, Palmer G, Gabay C (2007) Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 40, 216- 225. (Pubitemid 350213434)
14. Kobori A, Yagi Y, Imaeda H, Ban H, Bamba S, Tsujikawa T, Saito Y, Fujiyama Y, Andoh A (2010) Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol 45, 999-1007.
15. Llano DA, Li J,Waring JF, Ellis T, Devanarayan V,Witte DG, Lenz RA (2011) Cerebrospinal fluid cytokine dynamics differ between Alzheimer disease patients and elderly controls. Alzheimer Dis Assoc Disord 26, 322-328.
16. Espinassous Q, Garcia-de-Paco E, Garcia-Verdugo I, Synguelakis M, von Aulock S, Sallenave JM, McKenzie AN, Kanellopoulos J (2009) IL-33 enhances lipopolysaccharideinduced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol 183, 1446-1455.
17. Theoharides TC, Zhang B, Kempuraj D, Tagen M, Vasiadi M, Angelidou A, Alysandratos KD, Kalogeromitros D, Asadi S, Stavrianeas N, Peterson E, Leeman S, Conti P (2010) IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci U S A 107, 4448-4453.
18. Li M, Li Y, Liu X, Gao X, Wang Y (2012) IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. J Neuroimmunol 247, 25-31.
19. Liew FY, Pitman NI, McInnes IB (2010) Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 10, 103-110.
20. Thangavel R, Kempuraj D, Stolmeier D, Anantharam P, Khan M, Zaheer A (2013) Glia maturation factor expression in entorhinal cortex of Alzheimer's disease brain. Neurochem Res 38, 1777-1784.
21. Zaheer A, Mathur SN, Lim R (2002) Overexpression of glia maturation factor in astrocytes leads to immune activation of microglia through secretion of granulocyte-macrophagecolony stimulating factor. Biochem Biophys ResCommun294, 238-244. (Pubitemid 34694083)
22. Zaheer A,Yorek MA, Lim R (2001) Effects of glia maturation factor overexpression in primary astrocytes on MAP kinase activation, transcription factor activation, and neurotrophin secretion. Neurochem Res 26, 1293-1299. (Pubitemid 34184028)
23. Ojala J, Alafuzoff I, Herukka SK, van Groen T, Tanila H, Pirttila T (2009) Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients. Neurobiol Aging 30, 198-209.
24. Sutinen EM, Pirttila T, Anderson G, Salminen A, Ojala JO (2012) Pro-inflammatory interleukin-18 increases Alzheimer's disease-associated amyloid-beta production in human neuron-like cells. J Neuroinflammation 9, 199.
25. Christophi GP, Gruber RC, Panos M, Christophi RL, Jubelt B, Massa PT (2012) Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. Clin Immunol 142, 308-319.
26. Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic N, Lukic ML (2012) IL-33/ST2 axis in inflammation and immunopathology. Immunol Res 52, 89-99.
27. Han P, Mi WL, Wang YQ (2011) Research progress on interleukin-33 and its roles in the central nervous system. Neurosci Bull 27, 351-357.
28. Ruan L, Kang Z, Pei G, Le Y (2009) Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease. Curr Alzheimer Res 6, 531-540.
29. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM (2004) Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 10, 719-726. (Pubitemid 38937637)
30. Sastre M, Klockgether T, Heneka MT (2006) Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci 24, 167-176. (Pubitemid 43294623)
31. Meraz-RiosMA,Toral-Rios D, Franco-Bocanegra D,Villeda- Hernandez J, Campos-Pena V (2013) Inflammatory process in Alzheimer's Disease. Front Integr Neurosci 7, 59.
32. Marx CE, Jarskog LF, Lauder JM, Lieberman JA, Gilmore JH (2001) Cytokine effects on cortical neuronMAP-2immunoreactivity: implications for schizophrenia. Biol Psychiatry 50, 743-749. (Pubitemid 33086761)
33. Chapuis J, Hot D, Hansmannel F, Kerdraon O, Ferreira S, Hubans C, Maurage CA, Huot L, Bensemain F, Laumet G, Ayral AM, Fievet N, Hauw JJ, DeKosky ST, Lemoine Y, Iwatsubo T, Wavrant-Devrieze F, Dartigues JF, Tzourio C, Buee L, Pasquier F, Berr C, Mann D, Lendon C, Alperovitch A, Kamboh MI, Amouyel P, Lambert JC (2009) Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol Psychiatry 14, 1004-1016.
34. Yu JT, Song JH, Wang ND, Wu ZC, Zhang Q, Zhang N, Zhang W, Xuan SY, Tan L. (2012) Implication of IL-33 gene polymorphism in Chinese patients with Alzheimer's disease. Neurobiol Aging 33, 1014 e1011-1014.
35. Pei C, Barbour M, Fairlie-Clarke KJ, Allan D, Mu R, Jiang HR (2014) Emerging role of interleukin-33 in autoimmune diseases. Immunology 141, 9-17.
36. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptorrelated protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490. (Pubitemid 41587888)
37. Kempuraj D, Khan MM, Thangavel R, Xiong Z, Yang E, Zaheer A (2013) Glia maturation factor induces interleukin-33 release from astrocytes: Implications for neurodegenerative diseases. J Neuroimmune Pharmacol 8, 643-650.
38. Jana M, Anderson JA, Saha RN, Liu X, Pahan K (2005) Regulation of inducible nitric oxide synthase in proinflammatory cytokine-stimulated human primary astrocytes. Free Radic Biol Med 38, 655-664. (Pubitemid 40416861)